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History: The first investigational study on the use of extracorporeal photopheresis (ECP) was published 
in 1987, and focused on treatment of cutaneous T-cell lymphoma.1 This study led the FDA to approve of 
photopheresis. Although T-cell lymphoma is the only FDA approved indication for photopheresis its 
therapeutic use has expanded to a number of other disease processes, most notably acute and chronic 
graft versus host disease (GVHD).   
 
Photopheresis Procedure:  ECP is a leukapheresis-based therapy. Whole blood is processed outside of 
the body in the following way: whole blood is drawn from a catheter placed in a central vein; using 
centrifugation the different constituents of blood are separated based upon density i.e. white blood 
cells (WBC) separate into the buffy coat which can distinguished from red blood cells (RBCs) and 
plasma.2 The RBCs and plasma are returned to the patient, but the buffy coat containing the WBCs is 
isolated (it should be noted that only 5-10% of the patients WBCs are typically captured during the 
procedure). Thereafter, 8-methoxypsoralen (8-MOP) is added directly to buffy coat; WBCs mixed with 
the psoralen 8-MOP, are exposed to UVA light; the buffycoat with the WBCs are returned to the patient 
and the procedure is completed.   
 
Mechanism of Action of Photopheresis:   “Although ECP has been in clinical use for more than 25 years 
and is widely used for a variety of clinical entities, the mode of action remains elusive.”2 There has been 
minimal investigation into the mechanism since the 1980s. While it is known that 8-MOP leads to DNA 
crosslinking and WBC apoptosis, this mechanism alone is insufficient to explain the clinical/therapeutic 
effects of ECP. More recently, it has been found that ECP leads to an increase in CD4+ CD25+ T-
regulatory T-cells, which are important for regulating and preventing autoimmunity. Therefore an 
alternative hypothesis from induced cellular apoptosis is that ECP releases a milieu of cytokines that 
decrease autoimmunity without increasing risk of opportunistic infections. 
 
Conditions Treated: ECP has been utilized in treatment of cutaneous T-cell lymphoma, acute and 
chronic GVHD, scleroderma, solid organ transplant, Crohn’s disease, atopic dermatitis, type-1 diabetes 
mellitus, pemphigus, epidermolysis bullosa acquisita, erosive lichen planus, and systemic lupus 
erythematosus. 
 
Recommendations for Acute GVHD: ECP is currently recommended as second line therapy for patients 
with acute GVHD, grade II – IV disease who are steroid refractory, steroid dependent or steroid 
intolerant.3 Infective causes of diarrhea should be excluded, though acute GVHD can be concomitant 
with infection. Two treatments/procedures of photopheresis on separate days should be initiated 
weekly for a minimum of eight cycles (8 weeks). Patients with grade IV aGVHD may benefit from three 
treatments per week for the first 4 weeks. Patients who have progressive aGVHD during this time may 
require additional therapy at the discretion of the treating physician. Our center recommends this initial 
course of therapy for progressive/refractory chronic GVHD too.  
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